Amarin Corporation plc (NASDAQ: AMRN) (Amarin), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced new data from a post hoc analysis of the ...

New REDUCE-IT data presented at EAS 2026 suggests risk-weighted apoB could better identify residual cardiovascular risk in ...

People whose LDL cholesterol is in the normal range—even those without metabolic risk factors—may yet have levels of apolipoprotein B (apoB) that predict an elevated risk of future atherosclerotic ...

Modern medicine is improving in precision, identifying exactly who needs treatment and who doesn’t. In heart disease prevention, ApoB may outperform traditional cholesterol measures in predicting risk ...

Researchers at UT Southwestern Medical Center have identified a protein that acts as a key regulator of how the liver releases cholesterol carrying ...